Predicting response to opiate antagonists and placebo in the treatment of pathological gambling

Psychopharmacology

Volumn 200, Issue 4, 2008, Pages 521-527

  Grant, Jon E ^a   Kim, Suck Won ^a   Hollander, Eric ^b   Potenza, Marc N ^c,d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Impulse control disorders; Impulsivity; Opiate antagonists; Pharmacotherapy; Placebo

Indexed keywords

NALMEFENE; NALTREXONE; OPIATE ANTAGONIST; PLACEBO;

ADOLESCENT; ADULT; ALCOHOLISM; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ALCOHOLISM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GAMBLING; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PREDICTIVE VALUE OF TESTS; PSYCHOMETRICS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 52649104059     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1235-3     Document Type: Article

References (35)

1. RF Anton DH Moak LR Waid PK Latham RJ Malcolm JK Dias 1999 Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial Am J Psychiatry 156 11 1758 1764
2. RF Anton SS O'Malley DA Ciraulo RA Cisler D Couper DM Donovan DR Gastfriend JD Hosking BA Johnson JS LoCastro R Longabaugh BJ Mason ME Mattson WR Miller HM Pettinati CL Randall R Swift RD Weiss LD Williams A Zweben COMBINE Study Research Group 2006 Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295 17 2003 2017
3. C Blanco P Moreyra EV Nunes J Sáiz-Ruiz A Ibáñez 2001 Pathological gambling: addiction or compulsion? Sem Clin Neuropsychiatry 6 3 167 176
4. JA Brewer MN Potenza 2008 The neurobiology and genetics of impulse control disorders: Relationships to drug addictions Biochem Pharmacol 75 1 63 75
5. CL Broekkamp AG Phillips 1979 Facilitation of self-stimulation behavior following intracerebral microinjections of opioids into the ventral tegmental area Pharmacol Biochem Behav 11 3 289 295
6. RA Chambers JR Taylor MN Potenza 2003 Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability Am J Psychiatry 160 6 1041 1052
7. R de la Fuente-Fernández S Lidstone AJ Stoessl 2006 Placebo effect and dopamine release J Neural Transm Suppl 70 415 418
8. B Dell'Osso AC Altamura A Allen D Marazziti E Hollander 2006 Epidemiologic and clinical updates on impulse control disorders: a critical review Eur Arch Psychiatry Clin Neurosci 256 8 464 475
9. First MB, Spitzer RL, Gibbon M, Williams JBW (1995) Structured Clinical Interview for DSM-IV-Patient Edition (SCID-I/P, Version 2.0). New York Biometrics Research Department, New York State Psychiatric Institute, New York
10. Grant JE, Potenza MN (2007) Treatments for pathological gambling and other impulse control disorders. In: Nathan PE, Gorman JM (eds) A guide to treatments that work, 3rd edition. Oxford University Press, New York, pp 561-571
11. JE Grant MN Potenza E Hollander R Cunningham-Williams T Nurminen G Smits A Kallio 2006 A multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling Am J Psychiatry 163 2 303 312
12. JE Grant SW Kim BK Hartman 2008 A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, for the treatment of pathological gambling urges J Clin Psychiatry 69 5 783 789
13. M Hamilton 1959 The assessment of anxiety states by rating Br J Med Psychol 32 1 50 55
14. M Hamilton 1960 A rating scale for depression J Neurol Neurosurg Psychiatry 23 56 62
15. E Hollander CM DeCaria JN Finkell T Begaz CM Wong C Cartwright 2000 A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling Biol Psychiatry 47 9 813 817
16. E Hollander S Pallanti A Allen E Sood N Baldini Rossi 2005 Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 162 1 137 145
17. SW Kim JE Grant DE Adson YC Shin 2001 Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling Biol Psychiatry 49 11 914 921
18. TR Kosten HD Kleber C Morgan 1989 Role of opioid antagonists in treating intravenous cocaine abuse Life Sci 44 13 887 892
19. S Krishnan-Sarin JH Krystal J Shi B Pittman SS O'Malley 2007 Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking Biol Psychiatry 62 6 694 697
20. JH Krystal JA Cramer WF Krol GF Kirk RA Rosenheck Veterans Affairs Naltrexone Cooperative Study 425 Group 2001 Naltrexone in the treatment of alcohol dependence. N Engl J Med 345 24 1734 1739
21. HR Lesieur SB Blume 1987 The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers Am J Psychiatry 144 9 1184 1188
22. WR Martin DR Jasinski PA Mansky 1973 Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry 28 6 784 791
23. BJ Mason FR Salvato LD Williams EC Ritvo RB Cutler 1999 A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence Arch Gen Psychiatry 56 8 719 724
24. RT Matthews DC German 1984 Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine Neuroscience 11 3 617 625
25. J Monterosso BA Flannery HM Pettinati DW Oslin M Rukstalis CP O'Brien J Volpicelli 2001 Predicting treatment response to naltrexone: the influence of craving and family history Am J Addict 10 3 258 268
26. SA Montgomery 1999 The failure of placebo-controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna, European College of Neuropsychopharmacology Eur Neuropsychopharmacol 9 3 271 276
27. CP O'Brien 2005 Anti-craving (relapse prevention) medications: possible a new class of psychoactive medication Am J Psychiatry 162 1423 1431
28. DW Oslin W Berrettini H Krnazler H Pettinati J Gelernter J Volpicelli CP O'Brien 2003 A functional polymorphism of the mu opioid receptor gene is associated with naltrexone response in alcohol dependent patients Neuropsychopharmacol 28 8 1546 1552
29. S Pallanti CM DeCaria JE Grant M Urpe E Hollander 2005 Reliability and validity of the Pathological Gambling Modification of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS) J Gambl Stud 21 4 431 443
30. LA Ray KE Hutchison 2007 Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study Arch Gen Psychiatry 64 9 1069 1077
31. Rosner B (1995) Fundamentals of Biostatistics, 4th ed. Duxbury, Belmont
32. DJ Scott CS Stohler CM Egnatuk H Wang RA Koeppe JK Zubieta 2007 Individual differences in reward responding explain placebo-induced expectations and effects Neuron 55 2 325 336
33. Sheehan DV (1983) The anxiety disease. Scribner's, New York
34. WS Slutske S Eisen WR True MJ Lyons J Goldberg M Tsuang 2000 Common genetic vulnerability for pathological gambling and alcohol dependence in men Arch Gen Psychiatry 57 666 673
35. JR Volpicelli AI Alterman M Hayashida CP O'Brien 1992 Naltrexone in the treatment of alcohol dependence Arch Gen Psychiatry 49 11 876 880